Increasing evidence suggests that furthermore to T cell dependent effector mechanisms, autoantibodies get excited about the pathogenesis of MS also, including demyelinating antibodies particular for myelin oligodendrocyte glycoprotein (MOG). We record that RTL551 therapy can invert disease development and decrease demyelination and axonal harm induced by rhMOG without suppressing the anti-MOG antibody response. This result… Continue reading Increasing evidence suggests that furthermore to T cell dependent effector mechanisms,